Oxazolidinones: Activity, mode of action, and mechanism of resistance

International Journal of Antimicrobial Agents

Volumn 23, Issue 2, 2004, Pages 113-119

  Bozdogan, Bülent ^a   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Mechanism; Oxazolidinones; Resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; EPEREZOLID; GENTAMICIN; GLYCOPEPTIDE; ISONIAZID; LINEZOLID; MACROLIDE; MCB 3130; MCB 3382; METICILLIN; N [[3 (4 ACETYLPHENYL) 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; N [[3 [4 (METHYLSULFINYL)PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; OCID 0050; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANBEZOLID; RBX 8700; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN; VRC 3837; VRC 3924; VRC 4530;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BONE MARROW SUPPRESSION; CANDIDA ALBICANS; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG APPROVAL; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SENSITIVITY; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR INTERACTION; MORAXELLA CATARRHALIS; NEUROPATHY; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; PROSTHESIS INFECTION; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; SURGICAL INFECTION; THROMBOCYTOPENIA;

EID: 0842263829     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.11.003     Document Type: Review

References (75)

1. Eady E.A., Cove J.H. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus-an emerging problem for the management of skin and soft tissue infections. Curr. Opin. Infect. Dis. 16:2003;103-124.
2. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States. Morbidity and Mortality Weekly Report 2002;51:565-7.
3. Centers for Disease Control and Prevention. Public Health Dispatch: Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. Morbidity and Mortality Weekly Report 2002;51:902-3.
4. Kauffman C.A. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J. Antimicrob. Chemother. 51:2003;23-30.
5. Patel R. Clinical impact of vancomycin-resistant enterococci. J. Antimicrob. Chemother. 51:2003;13-21.
6. Leclercq R. Enterococci acquire new kinds of resistance. Clin. Infect. Dis. 24:1997;S80-S84.
7. Appelbaum P.C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:1992;77-83.
8. Slee A.M., Wuonola M.A., McRipley R.J., Zajac I., Zawada M.J., Bartholomew P.T.et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 31:1987;1791-1797.
9. Brickner S.J., Hutchinson D.K., Barbachyn M.R., Manninen P.R., Ulanowicz D.A., Garmon S.A.et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J. Med. Chem. 39:1996;673-679.
10. Diekema D.J., Jones R.N. Oxazolidinone antibiotics. Lancet. 358:2001;1975-1982.
11. Hoellman D.B., Lin G., Ednie L.M., Rattan A., Jacobs M.R., Appelbaum P.C. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob Agents Chemother. 47:2003;1148-1150.
12. Ueda Y., Sunagawa M. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria. Antimicrob Agents Chemother. 47:2003;2471-2480.
13. Mutnick A.H., Biedenbach D.J., Turnidge J.D., Jones R.N. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn. Microbiol. Infect. Dis. 43:2002;65-73.
14. Hoban D.J., Biedenbach D.J., Mutnick A.H., Jones R.N. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn. Microbiol. Infect. Dis. 45:2003;279-285.
15. Bolmstrom A., Ballow C.H., Qwarnstrom A., Biedenbach D.J., Jones R.N. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin. Microbiol. Infect. 8:2002;791-800.
16. Canton R., Loza E., Morosini M.I., Baquero F. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J. Antimicrob. Chemother. 50:2002;9-24.
17. Ballow C.H., Jones R.N., Biedenbach D.J. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. 43:2002;75-83.
18. Gemmell C.G. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J. Antimicrob. Chemother. 48:2001;47-52.
19. Henwood C.J., Livermore D.M., Johnson A.P., James D., Warner M., Gardiner A. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J. Antimicrob. Chemother. 46:2000;931-940.
20. Cercenado E., Garcia-Garrote F., Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J. Antimicrob. Chemother. 47:2001;77-81.
21. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; 12th Informational Supplement. NCCLS publication no. M100-S12, vol. 22, no. 1. Wayne (PA): National Committee for Clinical Laboratory Standards; 2002.
22. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003;52:864-8.
23. Peric M., Lin G., Clark C.L., Jacobs M.R., Appelbaum P.C. Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents. J. Antimicrob. Chemother. 50:2002;95-100.
24. Zhanel G.G., Palatnick L., Nichol K.A., Bellyou T., Low D.E., Hoban D.J. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47:2003;1867-1874.
25. Cha R., Rybak M.J. Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:2003;1984-1987.
26. Ednie L.M., Rattan A., Jacobs M.R., Appelbaum P.C. Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents. Antimicrob. Agents Chemother. 47:2003;1143-1147.
27. Hackbarth CJ, Gomez M, Asano RL, Luehr G, Gordeev M, Trias J. In vitro activity of new oxazolidinones against anaerobic bacteria. In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14-17 September 2003, Chicago (USA), Abstract F2101.
28. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., Schentag J.J. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36:2003;159-168.
29. French G. Safety and tolerability of linezolid. J. Antimicrob. Chemother. 51:2003;45-53.
30. Rana B., Butcher I., Grigoris P., Murnaghan C., Seaton R.A., Tobin C.M. Linezolid penetration into osteo-articular tissues. J. Antimicrob. Chemother. 50:2002;747-750.
31. Lovering A.M., Zhang J., Bannister G.C., Lankester B.J., Brown J.H., Narendra G.et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J. Antimicrob. Chemother. 50:2002;73-77.
32. Gill C.J., Murphy M.A., Hamer D.H. Treatment of Staphylococcus epidermidis ventriculo-peritoneal shunt infection with linezolid. J. Infect. 45:2002;129-132.
33. Moylett E.H., Pacheco S.E., Brown-Elliott B.A., Perry T.R., Buescher E.S., Birmingham M.C.et al. Clinical experience with linezolid for the treatment of nocardia infection. Clin. Infect. Dis. 36:2003;313-318.
34. Honeybourne D., Tobin C., Jevons G., Andrews J., Wise R. Intrapulmonary penetration of linezolid. J. Antimicrob. Chemother. 51:2003;1431-1434.
35. Gentry-Nielsen M.J., Olsen K.M., Preheim L.C. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother. 46:2002;1345-1351.
36. Chien J.W., Kucia M.L., Salata R.A. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin. Infect. Dis. 30:2000;146-151.
37. Babcock H.M., Ritchie D.J., Christiansen E., Starlin R., Little R., Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin. Infect. Dis. 32:2001;1373-1375.
38. Rao N., White G.J. Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin. Infect. Dis. 35:2002;902-904.
39. Patel R., Rouse M.S., Piper K.E., Steckelberg J.M. Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob. Agents Chemother. 45:2001;621-623.
40. Whitener CJ, Park SY, Browne FA, Parent LJ, Julian K, Bozdogan B, et al. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure, Clin Infect Dis, in press.
41. McNeil S.A., Clark N.M., Chandrasekar P.H., Kauffman C.A. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin). Clin. Infect. Dis. 30:2000;403-404.
42. Schulin T., Thauvin-Eliopoulos C., Moellering R.C. Jr., Eliopoulos G.M. Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 43:1999;2873-2876.
43. Ashtekar D.R., Costa-Periera R., Shrinivasan T., Iyyer R., Vishvanathan N., Rittel W. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis. 14:1991;465-471.
44. Wallace R.J. Jr., Brown-Elliott B.A., Ward S.C., Crist C.J., Mann L.B., Wilson R.W. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 45:2001;764-767.
45. Cynamon M.H., Klemens S.P., Sharpe C.A., Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents. Chemother. 43:1999;189-191.
46. Malhotra S, Gautham R, Bhadauriya T, Malhotra S, Rudra S, Das B. In vivo activity of RBx 8700 against Mycobacterium tuberculosis. In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14-17 September 2003, Chicago (USA), Abstract F-2106.
47. Corallo C.E., Paull A.E. Linezolid-induced neuropathy. Med. J. Aust. 177:2002;332.
48. Mueller F., Doring T., Erdemir T., Greuer B., Junke N., Osswald M.et al. Getting closer to an understanding of the three-dimensional structure of ribosomal RNA. Biochem. Cell Biol. 73:1995;767-773.
49. La Teana A., Gualerzi C.O., Dahlberg A.E. Initiation factor IF 2 binds to the alpha-sarcin loop and helix 89 of Escherichia coli 23S ribosomal RNA. RNA. 7:2001;1173-1179.
50. Malhotra A., Penczek P., Agrawal R.K., Gabashvili I.S., Grassucci R.A., Junemann R.et al. Escherichia coli 70 S ribosome at 15 A resolution by cryo-electron microscopy: localization of fMet-tRNAfMet and fitting of L1 protein. J. Mol. Biol. 280:1998;103-116.
51. Agrawal R.K., Heagle A.B., Penczek P., Grassucci R.A., Frank J. EF-G-dependent GTP hydrolysis induces translocation accompanied by large conformational changes in the 70S ribosome. Nat. Struct. Biol. 6:1999;643-647.
52. Kirillov S.V., Wower J., Hixson S.S., Zimmermann R.A. Transit of tRNA through the Escherichia coli ribosome: cross-linking of the 3′ end of tRNA to ribosomal proteins at the P and E sites. FEBS Lett. 514:2002;60-66.
53. Burkhardt N., Junemann R., Spahn C.M., Nierhaus K.H. Ribosomal tRNA binding sites: three-site models of translation. Crit. Rev. Biochem. Mol. Biol. 33:1998;95-149.
54. Zhou C.C., Swaney S.M., Shinabarger D.L., Stockman B.J. 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob. Agents Chemother. 46:2002;625-629.
55. Lin A.H., Murray R.W., Vidmar T.J., Marotti K.R. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents Chemother. 41:1997;2127-2131.
56. Shinabarger D.L., Marotti K.R., Murray R.W., Lin A.H., Melchior E.P., Swaney S.M.et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother. 41:1997;2132-2136.
57. Swaney S.M., Aoki H., Ganoza M.C., Shinabarger D.L. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42:1998;3251-3255.
58. Aoki H., Dekany K., Adams S.L., Ganoza M.C. The gene encoding the elongation factor P protein is essential for viability and is required for protein synthesis. J. Biol. Chem. 272:1997;32254-32259.
59. Bobkova E.V., Yan Y.P., Jordan D.B., Kurilla M.G., Pompliano D.L. Catalytic properties of mutant 23S ribosomes resistant to oxazolidinones. J. Biol. Chem. 278:2003;9802-9807.
60. Engemann JJ, Joyce MJ, Harrell LJ, Evans S, Reller L, Sexton D. Outbreak of linezolid-resistant Enterococcus faecium bloodstream infections on an oncology ward. In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14-17 September 2003, Chicago (USA), Abstract K-1112.
61. Jones RN, Anderegg TR, Biedenbach DJ, Mutnick A. First Annual Report from the Worldwide ZAAPS Oxazolidinone Resistance and Usage Surveillance Program (2002). In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14-17 September 2003, Chicago (USA), Abstract C2-2172.
62. Jones R.N., Della-Latta P., Lee L.V., Biedenbach D.J. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 42:2002;137-139.
63. Auckland C., Teare L., Cooke F., Kaufmann M.E., Warner M., Jones G.et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50:2002;743-746.
64. Johnson A.P., Tysall L., Stockdale M.V., Woodford N., Kaufmann M.E., Warner M.et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur. J. Clin. Microbiol. Infect Dis. 21:2002;751-754.
65. Chowdhry TK, Marshall SH, Donskey CJ, Salata RA, Rice LB. Emergence of linezolid-resistance in Enterococcus faecium. In: Proceedings of the ASM 100th General Meeting. 21-25 May 2000. Los Angeles (USA), Abstract.
66. Prystowsky J., Siddiqui F., Chosay J., Shinabarger D.L., Millichap J., Peterson L.R.et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45:2001;2154-2156.
67. Zurenko GE, Todd WM, Hafkin B, Meyers B, Kauffman C, Bock J, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. In: Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 26-29 September 1999, San Fransisco (USA), Abstract C-848.
68. Xiong L., Kloss P., Douthwaite S., Andersen N.M., Swaney S., Shinabarger D.L.et al. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J. Bacteriol. 182:2000;5325-5331.
69. Bozdogan B, Patel MV, Gupte SV, de Souza N, Khorakiwala H, Sreenivas K, et al. Characterisation of linezolid resistant mutants of Staphylococcus aureus and Streptococcus pneumoniae isolated from mouse in terms of 23S rRNA mutations. In: Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 27-30 September 2002, San Diego (USA), Abstract C1 1609.
70. Vendenbos F, Galimand M, Carsenti H, Pradier C, Roger PM, Dunais B, et al. Mechanism of resistance to linezolid in Streptococcus pneumoniae. In: Proceedings of 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14-17 September 2003, Chicago (USA), Abstract C1-2126.
71. Murray R.W., Schaadt R.D., Zurenko G.E., Marotti K.R.et al. Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay. Antimicrob. Agents Chemother. 42:1998;947-950.
72. Renslo AR, Jaishankar P, Venkatachalam R, Hackbarth C, Gómez M, Trias J, et al. Antimicrobial activity of novel azabicyclo[3.1.0] phenyloxazolidinones. In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14-17 September 2003, Chicago (USA), Abstract F-2100.
73. Samuel MM, Agrawal SK, Comparative in vitro activity of new oxazolidinone OCID 0050, linezolid, vancomycin, and teicoplanin against oxacillin resistant staphylococci. In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14-17 September 2003, Chicago (USA), Abstract F-2103.
74. Locher HH, Borer Y, Gaertner M, Schroeder S, Specklin JL, Hubschwerlen C. Antibacterial characterization and mode of action of new oxazolidinone- quinolone hybrids. In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14-17 September 2003, Chicago (USA), Abstract F-2145.
75. Hubschwerlen CN, Specklin J, Baeschlin DK, Sigwalt C, Haefeli S, Borer Y, et al. New oxazolidinone-quinolone hybrids; Synthesis and SAR. In: Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 14-17 September 2003, Chicago (USA), Abstract F-2144.